BR112014029577A2 - uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono - Google Patents

uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono

Info

Publication number
BR112014029577A2
BR112014029577A2 BR112014029577A BR112014029577A BR112014029577A2 BR 112014029577 A2 BR112014029577 A2 BR 112014029577A2 BR 112014029577 A BR112014029577 A BR 112014029577A BR 112014029577 A BR112014029577 A BR 112014029577A BR 112014029577 A2 BR112014029577 A2 BR 112014029577A2
Authority
BR
Brazil
Prior art keywords
sleep disorders
inverse
ghrelin receptor
treatment
antagonists
Prior art date
Application number
BR112014029577A
Other languages
English (en)
Inventor
Sonnenberg Gabriele
Jackson Margaret
S Denney William
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112014029577A2 publication Critical patent/BR112014029577A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono” a presente invenção se refere aos métodos de tratamento de transtornos do sono em pacientes compreendendo administração de um agonista ou antagonista inverso do receptor de grelina. a invenção também inclui métodos de tratamento de transtornos do sono compreendendo a administração de uma composição farmacêutica compreendendo um agonista ou antagonista inverso do receptor de grelina e pelo menos um veículo farmaceuticamente aceitável, diluente ou excipiente.
BR112014029577A 2012-06-04 2013-05-21 uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono BR112014029577A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261655177P 2012-06-04 2012-06-04
US201361812416P 2013-04-16 2013-04-16
PCT/IB2013/054177 WO2013182933A1 (en) 2012-06-04 2013-05-21 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Publications (1)

Publication Number Publication Date
BR112014029577A2 true BR112014029577A2 (pt) 2017-06-27

Family

ID=48700662

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029577A BR112014029577A2 (pt) 2012-06-04 2013-05-21 uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono

Country Status (16)

Country Link
US (1) US9370516B2 (pt)
EP (1) EP2854856B1 (pt)
JP (1) JP6165852B2 (pt)
KR (1) KR101708989B1 (pt)
CN (1) CN104334193A (pt)
AU (1) AU2013273263B2 (pt)
BR (1) BR112014029577A2 (pt)
CA (1) CA2874196C (pt)
ES (1) ES2716303T3 (pt)
HK (1) HK1202459A1 (pt)
IL (1) IL235883A0 (pt)
MX (1) MX2014014813A (pt)
RU (1) RU2600895C2 (pt)
SG (1) SG11201407387UA (pt)
WO (1) WO2013182933A1 (pt)
ZA (1) ZA201408672B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175272A (zh) * 2015-08-31 2015-12-23 吴玲 制备r-5-溴-1-氨基茚满的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
BR0317586A (pt) * 2002-12-20 2005-11-22 Mclean Hospital Corp Compostos para normalização do ciclo sono/vigìlia
US20050171132A1 (en) 2003-09-26 2005-08-04 Zhili Xin Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
EP1749208A2 (en) * 2004-05-14 2007-02-07 Novo Nordisk A/S Functional ghs-r antagonists
EP2043634A2 (en) * 2006-07-12 2009-04-08 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
WO2011114271A1 (en) 2010-03-19 2011-09-22 Pfizer Inc. 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor

Also Published As

Publication number Publication date
RU2014146109A (ru) 2016-07-27
SG11201407387UA (en) 2014-12-30
EP2854856B1 (en) 2019-01-23
CA2874196A1 (en) 2013-12-12
RU2600895C2 (ru) 2016-10-27
ES2716303T3 (es) 2019-06-11
US20150119381A1 (en) 2015-04-30
CN104334193A (zh) 2015-02-04
KR20150013236A (ko) 2015-02-04
AU2013273263B2 (en) 2017-08-24
MX2014014813A (es) 2015-02-12
EP2854856A1 (en) 2015-04-08
AU2013273263A1 (en) 2014-11-27
KR101708989B1 (ko) 2017-02-21
ZA201408672B (en) 2016-09-28
CA2874196C (en) 2016-12-06
JP2015518876A (ja) 2015-07-06
IL235883A0 (en) 2015-01-29
WO2013182933A1 (en) 2013-12-12
JP6165852B2 (ja) 2017-07-19
US9370516B2 (en) 2016-06-21
HK1202459A1 (en) 2015-10-02

Similar Documents

Publication Publication Date Title
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
MX369576B (es) Imidazoles 2-piridilo sustituidos como inhibidores de alk5 y/o alk4.
JO3078B1 (ar) مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
MX369518B (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
BRPI0907220A2 (pt) métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf
EA202091356A1 (ru) A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
BR112016008060A8 (pt) composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112015030953A8 (pt) compostos de piridina fundidos de heterociclo de cinco membros, método de produzir os mesmos, e uso dos mesmos
BR112014029577A2 (pt) uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono
BR112013025610A2 (pt) uso de um metapneumovírus aviário vivo, e, composição farmacêutica
PH12016500980B1 (en) Amide derivatives for gpr119 agonist

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]